Compare Moderna, Inc. (MRNA) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Prospect Capital Corporation — how do they compare? Moderna, Inc. trades at $206.43 (market cap $78.65B), while Prospect Capital Corporation trades at $1.8 (market cap $974.22M). The key difference: Moderna, Inc. is far larger — about 80.7× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 23.01% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Prospect Capital Corporation for 78 Days on average.
| MRNA | PSEC | |
|---|---|---|
Market Cap | $78.65B | $974.22M |
Volume | 37,373,437 | 5,779,996 |
Sector | Health | Financials |
52-Week High | $203.46 | $3.05 |
52-Week Low | $22.36 | $1.82 |
Typical Hold Time | 59 Days | 78 Days |
Enterprise Value | $74.80B | $2.73B |
Dividend Yield | — | 23.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
PSEC trades at $1.84, up 0.55% on the day, with a bearish technical signal from moving averages despite bullish RSI readings. The company reported negative revenue and net income for 2025, though recent quarterly EPS have beaten expectations. Dividend distributions continue, but analyst consensus is mixed with a majority hold rating. Recent news highlights distribution announcements and management commentary on lower middle-market opportunities.
The outlook is cautious; PSEC's high yield and low P/B ratio present value, but persistent negative cash flow, volatile profitability, and a bearish technical trend pose significant risks. Investor sentiment is divided, with concerns over NAV erosion and portfolio contraction offset by income-focused appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
